Latest Licensing News

Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.

TruScreen Group reported a 42% increase in FY2026 sales driven by new market entries including India and Indonesia, alongside launching a large-scale cervical cancer screening program in Vietnam and submitting major UNITAID proposals.

Tolu Minerals has revealed two new high-grade gold vein discoveries at its Tolukuma Gold Mine in Papua New Guinea, underpinning an ambitious near-mine drilling campaign aimed at boosting resource growth.

Aspermont Limited (ASX:ASP) reported a 147% jump in net profit and 11% revenue growth for H1 FY26, driven by steady subscription growth and a ramp-up in non-subscription revenues. The company’s self-funded data and intelligence platform is on track, with Rio Tinto’s enterprise contract validating its strategic pivot.

Beonic Ltd (ASX:BEO) has initiated a $3 million pro-rata renounceable entitlement offer at $0.08 per share, partially underwritten by Alpine Capital, to shore up working capital and repay shareholder loans. The offer carries potential dilution of 35.7% for non-participating shareholders and may increase the Thorney Group's voting power significantly.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Acrux has amended its licensing agreement with Gedeon Richter to bring its Estradiol spray Lenzetto® to Australia, unlocking up to AUD 5.4 million in milestone payments and addressing a critical shortage in Menopause Hormone Therapy products.

Klevo Rewards takes a major step in building a regulated crypto-financial platform by partnering with Bybit and proposing key acquisitions to expand Fly Wallet’s digital asset and credit capabilities.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

Lithium Universe (ASX: LU7) has acquired exclusive global rights to a University of Edinburgh hydrometallurgical process that extracts gold and copper from electronic waste using recyclable organic compounds, positioning the company at the forefront of sustainable precious metals recovery.

Aguia Resources has received official commercialisation approval for its Pampafos phosphate fertiliser project, enabling invoicing and marketing ahead of a targeted sales campaign designed to boost cash flow by mid-2026.